Two-Drug attack on prostate cancer before surgery
NCT ID NCT06631521
Summary
This study is testing whether giving two hormone-blocking drugs (darolutamide and relugolix) before prostate removal surgery is safe and can shrink tumors in men with high-risk prostate cancer. The trial will enroll about 30 men to see if they can complete the drug treatment without severe side effects and to measure how much the tumors shrink. The goal is to see if this approach makes surgery more effective for controlling aggressive prostate cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER (ADENOCARCINOMA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
AdventHealth Orlando
RECRUITINGOrlando, Florida, 32803, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.